For Immediate Release

DIMERIX TO PRESENT AT NWR VIRTUAL HEALTH CONFERENCE

MELBOURNE, Australia, 01 May 2020: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company, is pleased to provide an opportunity for shareholders and investors to join a virtual presentation by CEO & MD Dr Nina Webster, who will present at the NWR Virtual Health Conference to be held on Friday 1 May & Monday 4 May. A copy of the presentation is attached herewith.

Event: NWR Communications Virtual Health Conference
Presenting: Dr Nina Webster, CEO & Managing Director
Time/date: 10:45am AEST, Monday 4 May

The event is free and investors can register online to view the live presentation here: https://nwrhealthconf.webflow.io/

For further information, please visit our website at www.dimerix.com or contact:
Dr Nina Webster, Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Authorised for lodgement by the Board of the Company

—END—

About Dimerix
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving irbesartan, an angiotensin II type I (AT1) receptor blocker and the standard of care treatment for kidney disease. DMX-200 has granted patents in various territories until 2032.

In 2017, Dimerix completed its first Phase 2a study in patients with a range of chronic kidney diseases. No significant adverse safety events were reported, and all study endpoints were achieved. In a subsequent sub-group analysis, significant clinical efficacy signals were seen in the diabetic group.

DMX-200 administered to patients already taking stable irbesartan reduced proteinuria levels by a further 36%. This reduction in proteinuria is highly correlated with improved renal function and delay in kidney failure and dialysis. The compelling results from this study prompted the decision to initiate two different clinical studies in 2018: one for patients with Diabetic Kidney Disease; and the second for patients with another form of kidney disease, Focal Segmental Glomerulosclerosis (FSGS).

FSGS is a serious and rare disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and kidney failure and for which there is a recognised medical need for a new or improved treatment. FSGS affects both children and adults.

DMX-200 for FSGS has been granted Orphan Drug Designation by the FDA and EMA. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and an abbreviated regulatory pathway to approval.

About DMX-700

COPD is a progressive and life-threatening lung disease. The primary cause of COPD is exposure to tobacco smoke (either active smoking or secondary smoke), however is also caused by exposure to indoor and outdoor air pollution, occupational dusts and fumes and long-term asthma. COPD is the fourth-leading cause of death in the world and although treatments exist to improve the symptoms of COPD, there is currently no way to slow progression of the condition or cure it. Moreover, among the top five causes of death globally, this disease is the only one with increasing mortality rates. The global COPD treatment market was valued at US$14 billion in 2017 and is projected to increase at a compound annual growth rate of 4.9% to 2026.

Initial studies have been completed, and Dimerix has completed a key step in securing ownership over what it believes is an important new drug discovery by lodging a provisional patent application for DMX-700. Over the next 12 months Dimerix will conduct further proof of concept studies to perform the value added verification in support of a robust product development pathway and patent position.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com

Dimerix

a clinical stage biotech with a scalable, proprietary platform technology

4th May 2020

Dimerix

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

Dimerix

Corporate Snapshot (ASX:DXB)

Share price performance vs. ASX All Ords



$35m
Market capitalisation (AUD)

$0.20
Share price (AUD)

$3.5m
in cash & cash equivalents; (AUD)

456,626
Average daily share trading volume (12 months)

Research Coverage

Taylor Collison	20Nov2019	Rating: Buy	Price Target: A$0.51 *(pre-COVID-19)*
Argonaut	16Mar2020	Rating: Buy	Price Target: A$0.40 *(post-COVID-19)*

Dimerix

A pipeline of drugs identified using Receptor-HIT

Dimerix Technology Platform

- Patented cellular assay that enables understanding of real-time interactions of receptors including G Protein-Coupled Receptors (GPCRS) to drive the discovery of new drugs and research programs
- Programs based on the critical scientific rationale that GPCRs can act as a complex with other GPCRs and have novel pharmacology when in complex



Strategic Fit

- Dimerix is developing a **commercial pipeline** of drugs for GPCRs targeting chemokine pathway diseases with a **clear unmet need**
- Dimerix can utilise its current core **competencies** and **capabilities** to execute on the disclosed opportunities
- Dimerix has identified **new uses** for existing drugs to drive the **discovery** of new treatments and research programs
- Dimerix has **multiple products** in its pipeline, at different development stages, **diversifying** risk and increasing potential future sources of revenue

Dimerix

Development pipeline

3 product candidates in the pipeline, with 2 clinical read outs expected mid-2020

Compound	Disease Target	Preclinical	Phase 1	Phase 2	Pivotal Study	Market
DMX-200	Focal Segmental Glomerulosclerosis (FSGS)	*Phase 2a last patient, last dose June 2020*				
DMX-200	Diabetic Kidney Disease	*Phase 2 last patient, last dose July 2020*				
DMX-700	Chronic Obstructive Pulmonary Disease (COPD)					
DMX-XXX	Undisclosed (various)					



Dimerix

Dimerix strategy

- Clinical studies play a large part in the commercialisation plan but are by no means the only piece of the puzzle
- Maximising an opportunity requires integration of:



- Focus resources on R&D activities to achieve best outcome for the patients & shareholders

Dimerix

Diabetic kidney disease market dynamics

US market size 2018^

US$5.8 billion

Market growth will **accelerate** at a CAGR (2019-2022)^

5.1%

Addressable market

US$1.1 billion

Diabetic patients that have kidney disease*

40%

The market is highly concentrated, with few players occupying market share‡

Current standard of care control blood pressure levels: Angiotensin receptor blockers (ARBs)*

Diabetic kidney disease is the **leading cause** of Chronic Kidney Disease Worldwide*

Key driver is the rise in diabetes global incidence^

Dimerix

* *Alicic R, Rooney M, Tuttle K (2017) Diabetic Kidney Disease Challenges, Progress, and Possibilities, Clinical Journal of American Society of Nephrology [https://cjasn.asnjournals.org/content/12/12/2032] [Accessed 02Mar20]*

‡ *Technavio (2019); Global Diabetic Nephropathy Market 2018-2022 [https://www.businesswire.com/news/home/20181227005118/en/Global-Diabetic-Nephropathy-Market-2018-2022-34-CAGR] [Accessed 02Mar20]*

^ *Market Research Future (2020); Diabetic Neuropathy Treatment Market Research Report – Global Forecast to 2025 [https://www.marketresearchfuture.com/reports/diabetic-neuropathy-treatment-market-8359] [Accessed 02Mar20]*

FSGS market: serious and rare kidney disease

Orphan indication currently with **no FDA-approved** therapies‡

US **incidence‡**

80,583

Market growth will **accelerate** at a CAGR (2017-2025)#

>8.0%

Average orphan drug pricing

>US$7,000

per month*

Across all nephrotic syndromes, FSGS accounts for *‡

- 40% cases in **adult**
- 20% cases in **children**

30%-40% of FSGS transplant patients:
FSGS **disease recurs**^

Approximately 5 years from diagnosis to **end-stage renal disease‡**

More than 5,400 **new cases** diagnosed each year in US^

DMX-200 has US and EU Orphan Drug Designation for FSGS

Dimerix

* *Sangameswaran K, Baradhi K; (2019) Focal Segmental Glomerulosclerosis [https://www.ncbi.nlm.nih.gov/books/NBK532272/] [Accessed 02Mar20]*
^ *Nephcure Kidney International (2020); Focal Segmental Glomerulosclerosis [https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs/] [Accessed 02Mar20]*
‡ *Rosenberg A, Kopp J (2017); Focal Segmental Glomerulosclerosis, Clinical Journal of American Society of Nephrology [https://cjasn.asnjournals.org/content/12/3/502} [Accessed 02Mar20]*
ˈ *DelveInsight Market Research Report (2020); Focal Segmental Glomerulosclerosis (FSGS)- Market Insight, Epidemiology and Market Forecast -2030*
Transparency Market Research (2019); Focal Segmental Glomerulosclerosis (FSGS) Market [https://www.transparencymarketresearch.com/focal-segmental-glomerulosclerosis-market.html] [Accessed 02Mar20)

DMX-200 overview

New Chemical Entity
Never been FDA approved

DMX-200: a small molecule drug called propagermanium

- Twice daily, capsule administration for two different types of kidney disease
- Administered to patients already on standard of care treatment (irbesartan)
- Never been approved by a regulatory authority for clinical use in the US, Europe or Australia

DMX has completed a Phase 1 and a Phase 2a clinical studies in kidney disease:

Providing clinically and statistically significant results

Compelling data encouraged Dimerix to progress into 2 Phase 2 clinical studies:

- Phase 2 in Focal Segmental Glomerulosclerosis (FSGS) – an orphan indication
- Phase 2 in Diabetic Kidney Disease

Dimerix

*NCE can attract 5 years exclusivity in US and EU
(7 years in US and 10 years in EU for Orphan Drugs)

Causes of chronic kidney disease



Dimerix

DMX-200 proposed mechanism of action

DMX-200 addresses three key mechanisms that causes renal damage and sclerotic kidney disease

1
Hyperfiltration of and hypertension within blood vessels of the glomeruli



2
Inflammatory cell infiltration of the kidneys: subsequent fibrosis

3
Loss of specialised filtering cells called podocytes (cannot regenerate) from the glomeruli

Irbesartan blocks cellular receptors responsible for hyperfiltration & glomerular hypertension

DMX-200 inhibits chemokine receptor (CCR2), reducing the attraction of inflammatory cells into the kidneys

Certain kidney cells express both receptors, thus using only 1 compound does not block activation and results in only a partial response

DMX-200 unique proposition: total benefit is greater than the sum of the two individual effects

Dimerix

2017: DMX-200 Phase 2a study - diabetic sub-group

- In 2001 - Irbesartan studied in a large group of type 2 diabetics
  - Proteinuria levels reduced by 24%
- In 2017 - DXB Phase 2a study:

  DMX-200 + Irbesartan

In addition to irbesartan reduction, proteinuria levels reduced by a **<u>further 36%</u>** in diabetic sub-group

- *Reduction of proteinuria by >30% may increase time to dialysis by 3-5 years and reduce health costs by $100,000 per patient per year*



Dimerix

Current Phase 2 trial in diabetic kidney disease

- Phase 2, double-blind, randomised, placebo-controlled, crossover study evaluating the safety and efficacy of DMX-200 in patients with diabetic kidney disease who are receiving a stable dose of Irbesartan

n=40
(45 patients dosed)

Powered to resolve 30% reduction in ACR

Primary Endpoint: Efficacy % change in ACR



Last patient last dose scheduled July 2020

Fully recruited

Dimerix

Current Phase 2a trial in FSGS

- Phase 2a, double-blind, randomised, placebo-controlled, crossover study evaluating the safety and efficacy of DMX-200 in patients with primary FSGS who are receiving a stable dose of Irbesartan

n=10

Primary Endpoint: Safety



Last patient last dose scheduled June 2020

Fully recruited

Dimerix

Special Access Scheme for compassionate use



- **Therapeutic Goods Administration (TGA) Special Access Scheme (SAS):** access to therapeutic goods that that have not yet been approved in Australia - on a case by case basis
- Application made to TGA by the treating physician
- TGA approval takes into account the safety profile of DMX-200, as well as clinical evidence that DMX-200 may benefit patients and failure of any current therapies
- TGA approved SAS Category B applications for DMX-200
- Dimerix supplies the drug product once approved

Dimerix

DMX-200 regulatory overview



Dimerix

DMX-200 Intellectual property and exclusivity

Intellectual Property

US

2033 Method of use: any CCR2 antagonist with any ARB for any kidney disease

Patents granted
US 9,314,450
US 10,058,555
US 10,525,038

Patent applications with alternative claims filed

EU

2032 Method of use: DMX-200 with irbesartan

Patents granted
EP 2663304

Patent applications with alternative claims filed

Exclusivity

US

7 years FSGS orphan exclusivity

5 years DKD exclusivity

EU

10 years FSGS orphan exclusivity

8 years DKD exclusivity

DMX-200 has benefit of exclusivity whilst relying on existing safety data

Dimerix

Additional patents granted in other key territories

DMX-200 summary

Commercially attractive and growing market

Unmet need, with no current competition

DMX-200 compares favourably to compounds currently in development

Strong superior efficacy data in previous Phase 2a study

Product supply secured with FDA approved manufacturing facility



Orphan status for FSGS in both US & EU

Granted patents with additional patents pending

Existing long-term safety data available: lower development risk

Approved by TGA for compassionate use in Australia

Phase 2 data anticipated mid-2020 for both Phase 2 clinical studies

FDA confirmed non-clinical & CMC NDA package suitability + Ph3 study design principles

Additional assets to diversify risk and potential sources of revenue

Assets 100% owned by Dimerix

Financial Year 2019/2020 value driving events



Dimerix

FY = Financial Year; 01July-30June

DIMERIX (ASX:DXB)

End of Presentation

Dimerix

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. bd@dimerix.com